Partnerships Catalan Institute of Oncology: investigator-sponsored Phase 1 study; University of Pennsylvania: clinical trial agreement for Phase 1 huCART-meso cell combination study
Indications
pancreatic ductal adenocarcinoma (VIRAGE Phase 2b, IV with gemcitabine/nab-paclitaxel)(Phase 2)
Status note Lead product candidate; genetically modified oncolytic adenovirus based on HAd5. FDA Orphan Drug designation (June 2023) and Fast Track (May 2024) for pancreatic cancer; EMA COMP orphan recommendation (May 2011) for pancreatic cancer. VIRAGE Phase 2b randomized study ongoing; Phase 1 retinoblastoma data presented May 2025. Additional preclinical/clinical combination work (liposomal irinotecan, immunomodulators) not distinct assets.
Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
SYN-004
Lead indication
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam
—
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.